Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
NCT01317641
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
136
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
ODM-201
Sponsor
Orion Corporation, Orion Pharma
Collaborators
[object Object]